Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer.

Pharmaceuticals (Basel) · 2016 · PMC4932547 · PMID 27213406

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Aptamer HeA2_3 revealed a highly significant increase in binding to HER2-overexpressing cells (SKOV3 and SKBR3) compared to cells with low HER2 expression level (MDA-MB-231) at 500 nM concentration ( Figure 4 A).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.